慢性肾病患者接受影像检查时对比剂所致急性肾损伤的Meta分析
该Meta分析纳入6项研究共55963例参与者,评估慢性肾病(CKD)患者静脉注射对比剂后发生对比剂肾病的风险。结果显示,与未接受对比剂者相比,静脉注射对比剂未导致CKD患者肾功能恶化(OR 1.07,95%CI 0.98-1.17;I²=35.3%),各CKD分期亚组分析均未显示OR差异。
要点
- 静脉注射对比剂未显著增加CKD患者对比剂肾病风险(OR 1.07,95%CI 0.98-1.17)。
- 随着估算肾小球滤过率降低,接受静脉对比剂的患者比例减少。
- 各CKD分期亚组OR均无统计学显著差异,但部分亚组异质性较高。
核心结论
- 静脉注射对比剂未导致CKD患者肾功能恶化,各CKD分期亚组分析均未显示对比剂肾病OR差异;但作者指出回顾性研究存在局限,其他对比剂肾病风险因素可能分布不均。
研究设计与样本
- Meta分析,检索PubMed和MEDLINE截至2018年10月3日发表的文献,纳入6项研究共55,963例参与者,仅选择静脉途径给予对比剂的研究,采用Peto法和随机效应模型,按估算肾小球滤过率进行亚组分析。
诊断标准与关键数值
- 对比剂肾病风险以OR表示:总体OR 1.07(95%CI 0.98-1.17;I²=35.3%);CKD 2期OR 1.11(95%CI 0.95-1.30;I²=4.0%);CKD低于3期OR 1.05(95%CI 0.93-1.18;I²=48.3%);CKD 3期OR 1.06(95%CI 0.94-1.19;I²=32.0%);CKD低于4期OR 1.08(95%CI 0.84-1.39;I²=44.6%);CKD 4期OR 0.86(95%CI 0.37-2.00);CKD 5期仅一项研究,OR 0.26(95%CI 0.02-3.4)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文指出该回顾性研究存在局限,其他对比剂肾病风险因素可能分布不均。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. Contrast-induced nephropathy (CIN) generally is the main concern for patients with chronic kidney disease (CKD) undergoing contrast-enhanced imaging. To evaluate the risk of nephropathy induced by IV contrast medium (CM) in patients with CKD, we performed a meta-analysis. MATERIALS AND METHODS. We searched for PubMed and MEDLINE articles that were published up to October 3, 2018, contained the phrase "contrast medium" or "contrast media" and the word "renal," and included patients with CKD and a proper control group. The publications that were identified were reviewed, and only studies that used an IV route of CM administration were selected. Subgroup analysis was performed according to the estimated glomerular filtration rate. RESULTS. Six studies including 55,963 participants were selected. The Peto method and random-effects model were applied. IV infusion of CM did not lead to the deterioration of renal function in patients with CKD compared with those without CKD (odds ratio [OR], 1.07; 95% CI, 0.98-1.17; I2, 35.3%). As the estimated glomerular filtration rate decreased, fewer patients received IV CM. The ORs for CIN on the basis of CKD stage were as follows: 1.11 (95% CI, 0.95-1.30; I2, 4.0%) for stage 2 CKD, 1.05 (95% CI, 0.93-1.18, I2, 48.3%) for CKD lower than stage 3, 1.06 (95% CI, 0.94-1.19; I2, 32.0%) for stage 3 CKD, 1.08 (95% CI, 0.84-1.39; I2, 44.6%) for CKD lower than stage 4, 0.86 (95% CI, 0.37-2.00) for stage 4 CKD, and 0.26 (95% CI, 0.02-3.4) for stage 5 CKD in one study only. All analyses showed the lack of difference in the ORs for CIN between participants who received IV injection of CM and those who did not. CONCLUSION. Retrospective cohort studies of IV radiographic CM have failed to show renal damage in patients with CKD. This retrospective study is limited, and other risk factors for CIN might not be distributed evenly.
引用
- Lee YC, Hsieh CC, Chang TT, et al. Contrast-Induced Acute Kidney Injury Among Patients With Chronic Kidney Disease Undergoing Imaging Studies: A Meta-Analysis. AJR Am J Roentgenol. 2019. PMID: 31386574. doi:10.2214/AJR.19.21309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。